Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability

By sjmartinez • October 2, 2026

Maheswaran S, Dedeoglu AS, Niemierko A, Abelman RO, Jimenez R, Rieur O, Hutchinson J, Vidula N, Spring LM, Ellisen LW, Isakoff SJ, Wander SA, Bardia A, Medford AJ. Metastatic metaplastic triple negative breast cancer response to sacituzumab govitecan and biomarker targetability. Breast Cancer Res Treat. 2026 Sep 30;219(3):26. doi: 10.1007/s10549-026-08079-0. PMID: 42816667.

Tags: antibody–drug conjugates, Genomic profiling, Hematology/Oncology, Metaplastic breast cancer, Publications, Sacituzumab govitecan, triple-negative breast cancer

Delta-9-tetrahydrocannabinol alleviates inflammation by modulating immune responses in LPS-induced murine inflammation model

Tomer S, Harding J, Wang L, Kedia N, Cook E, Le V, Platt C, Le J, Tien N, Patalay K, Langfelder P, Yang XW, Zhang[...]

Self-Reported Cancer-Related Cognitive Impairment and Psychosocial Symptom Burden in Survivors of Head and Neck Cancer

Lin ME, Stenzel J, Delavary D, St John MA, Wong DJ, Ganz PA, Brauer ER. Self-Reported Cancer-Related Cognitive Impairment and Psychosocial Symptom Burden in Survivors[...]

A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers

Fakih M, Doi T, Tolcher A, Hong D, Tie J, Messersmith W, Koyama T, Rosen L, Borlido J, Damore MA, Delioukina M, Cheronis I, Clark[...]